Works matching Mantle cell lymphoma (MCL)

Results: 1472
    1

    Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.

    Published in:
    British Journal of Haematology, 2018, v. 183, n. 4, p. 578, doi. 10.1111/bjh.15567
    By:
    • Jain, Preetesh;
    • Kanagal‐Shamanna, Rashmi;
    • Zhang, Shaojun;
    • Ahmed, Makhdum;
    • Ghorab, Ahmad;
    • Zhang, Liang;
    • Ok, Chi Young;
    • Li, Shaoying;
    • Hagemeister, Frederick;
    • Zeng, Dongfeng;
    • Gong, Tiejun;
    • Chen, Wendy;
    • Badillo, Maria;
    • Nomie, Krystle;
    • Fayad, Luis;
    • Medeiros, Leonard J.;
    • Neelapu, Sattva;
    • Fowler, Nathan;
    • Romaguera, Jorge;
    • Champlin, Richard
    Publication type:
    Article
    2

    The Role of the Lawton Instrumental Activities of Daily Living (IADL) Scale in Predicting Adverse Events and Outcomes of R-CHOP Treatment in Elderly Patients with Diffuse Large B-Cell Lymphomas (DLBCLs) or Mantle Cell Lymphomas (MCLs): A Prospective Single-Center Study

    Published in:
    Cancers, 2024, v. 16, n. 24, p. 4170, doi. 10.3390/cancers16244170
    By:
    • Jabłonowska-Babij, Paula;
    • Olszewska-Szopa, Magdalena;
    • Potoczek, Stanisław;
    • Majcherek, Maciej;
    • Szeremet, Agnieszka;
    • Kujawa, Krzysztof;
    • Wróbel, Tomasz;
    • Czyż, Anna
    Publication type:
    Article
    3

    The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.

    Published in:
    International Journal of Cancer, 2021, v. 148, n. 1, p. 150, doi. 10.1002/ijc.33202
    By:
    • Roider, Tobias;
    • Wang, Xi;
    • Hüttl, Katrin;
    • Müller‐Tidow, Carsten;
    • Klapper, Wolfram;
    • Rosenwald, Andreas;
    • Stewart, James Peter;
    • Castro, David Gonzalez;
    • Dreger, Peter;
    • Hermine, Olivier;
    • Kluin‐Nelemans, Hanneke C.;
    • Grabe, Niels;
    • Dreyling, Martin;
    • Pott, Christiane;
    • Ott, German;
    • Hoster, Eva;
    • Dietrich, Sascha
    Publication type:
    Article
    4

    Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.

    Published in:
    Leukemia & Lymphoma, 2010, v. 51, n. 9, p. 1612, doi. 10.3109/10428194.2010.496507
    By:
    • Dreyling, Martin;
    • Hoster, Eva;
    • Bea, Silvia;
    • Hartmann, Elena;
    • Horn, Heike;
    • Hutter, Grit;
    • Salaverria, Itziar;
    • Pott, Christiane;
    • Trneny, Marek;
    • Le Gouill, Steven;
    • Cortelazzo, Sergio;
    • Szymczyk, Michal;
    • Jurczak, Wojciech;
    • Shpilberg, Ofer;
    • Ribrag, Vincent;
    • Hermine, Olivier
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11

    Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.

    Published in:
    British Journal of Haematology, 2005, v. 131, n. 1, p. 29, doi. 10.1111/j.1365-2141.2005.05716.x
    By:
    • Tiemann, Markus;
    • Schrader, Carsten;
    • Klapper, Wolfram;
    • Dreyling, Martin H.;
    • Campo, Elias;
    • Norton, Andrew;
    • Berger, Francoise;
    • Kluin, Philip;
    • Ott, German;
    • Pileri, Stephano;
    • Pedrinis, Ennio;
    • Feller, Alfred C.;
    • Merz, Hartmut;
    • Janssen, Dirk;
    • Hansmann, Martin L.;
    • Krieken, Han;
    • Möller, Peter;
    • Stein, Harald;
    • Unterhalt, Michael;
    • Hiddemann, Wolfgang
    Publication type:
    Article
    12
    13

    Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 582, doi. 10.1002/hon.3164_437
    By:
    • Melani, C. J.;
    • Lakhotia, R.;
    • Pittaluga, S.;
    • Phelan, J. D.;
    • Yang, Y.;
    • Davies‐Hill, T.;
    • Simard, J.;
    • Muppidi, J.;
    • Huang, D. W.;
    • Thomas, C. J.;
    • Ceribelli, M.;
    • Tosto, F. A.;
    • Pradhan, A.;
    • Juanitez, A. M.;
    • Rimsza, L. M.;
    • Jacob, A.;
    • Simmons, H.;
    • Steinberg, S. M.;
    • Jaffe, E. S.;
    • Staudt, L. M.
    Publication type:
    Article
    14

    The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 519, doi. 10.1002/hon.3164_384
    By:
    • Chiappella, A.;
    • Dodero, A.;
    • Ljevar, S.;
    • Pennisi, M.;
    • Bonifazi, F.;
    • De Philippis, C.;
    • Galli, E.;
    • Di Rocco, A.;
    • Tisi, M. C.;
    • Cutini, I.;
    • Carrabba, M. G.;
    • Musso, M.;
    • Martino, M.;
    • Barbui, A. M.;
    • Botto, B.;
    • Farina, M.;
    • Grillo, G.;
    • Patriarca, F.;
    • Ladetto, M.;
    • Arcaini, L.
    Publication type:
    Article
    15

    Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 472, doi. 10.1002/hon.3164_347
    By:
    • Wang, Y.;
    • Larson, M. C.;
    • Ekberg, S.;
    • Smedby, K. E.;
    • Zhao, E. J.;
    • Gerrie, A. S.;
    • Farooq, U.;
    • Maurer, M. J.;
    • Paludo, J.;
    • Nowakowski, G. S.;
    • Habermann, T. M.;
    • Albertsson‐Lindblad, A.;
    • Glimelius, I.;
    • Link, B. K.;
    • Diego, V.;
    • Jerkeman, M.;
    • Cerhan, J. R.
    Publication type:
    Article
    16

    CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 181, doi. 10.1002/hon.3163_114
    By:
    • Khouja, M.;
    • Genuardi, E.;
    • Ferrero, S.;
    • Alessandria, B.;
    • Verhagen, O. J.;
    • Homburg, C.;
    • van der Velden, V. H.;
    • Gameiro, P.;
    • Sanz, R. García;
    • Herrera, A. Medina;
    • Fronkova, E.;
    • Brüggemann, M.;
    • Dreyling, M.;
    • Hoster, E.;
    • Ladetto, M.;
    • Langerak, A. W.;
    • Darzentas, N.;
    • Pal, K.;
    • Stewart, P. J.;
    • Gonzalez de Castro, D.
    Publication type:
    Article
    17
    18

    Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).

    Published in:
    British Journal of Haematology, 2018, v. 182, n. 3, p. 404, doi. 10.1111/bjh.15411
    By:
    • Jain, Preetesh;
    • Romaguera, Jorge;
    • Srour, Samer A.;
    • Lee, Hun J.;
    • Hagemeister, Frederick;
    • Westin, Jason;
    • Fayad, Luis;
    • Samaniego, Felipe;
    • Badillo, Maria;
    • Zhang, Liang;
    • Nastoupil, Lorreta;
    • Kanagal‐Shamanna, Rashmi;
    • Fowler, Nathan;
    • Wang, Michael L.
    Publication type:
    Article
    19
    20
    21

    Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 6, p. 623, doi. 10.1002/ajh.25796
    By:
    • Zhao, Shuangtao;
    • Kanagal‐Shamanna, Rashmi;
    • Navsaria, Lucy;
    • Ok, Chi Young;
    • Zhang, Shaojun;
    • Nomie, Krystle;
    • Han, Guangchun;
    • Hao, Dapeng;
    • Hill, Holly A.;
    • Jiang, Changying;
    • Yao, Yixin;
    • Nastoupil, Loretta;
    • Westin, Jason;
    • Fayad, Luis;
    • Nair, Ranjit;
    • Steiner, Raphel;
    • Ahmed, Sairah;
    • Samaniego, Felipe;
    • Iyer, Swaminathan P.;
    • Oriabure, Onyeka
    Publication type:
    Article
    22
    23
    24

    S221: LONG‐TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967796.89942.03
    By:
    • Ladetto, Marco;
    • Tavarozzi, Rita;
    • Evangelista, Andrea;
    • Genuardi, Elisa;
    • Drandi, Daniela;
    • Mian, Michael;
    • Zanni, Manuela;
    • Cavallo, Federica;
    • Rocco, Alice DI;
    • Stefoni, Vittorio;
    • Pagani, Chiara;
    • Re, Alessandro;
    • Chiappella, Annalisa;
    • Balzarotti, Monica;
    • Zilioli, Vittorio Ruggero;
    • Da Silva, Maria Gomes;
    • Arcaini, Luca;
    • Molinari, Annalia;
    • Ballerini, Filippo;
    • Ferreri, Andrés José María
    Publication type:
    Article
    25
    26

    P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE.

    Published in:
    2023
    By:
    • Chiappella, Annalisa;
    • Dodero, Anna;
    • Ljevar, Silva;
    • Pennisi, Martina;
    • Bonifazi, Francesca;
    • De Philippis, Chiara;
    • Galli, Eugenio;
    • Rocco, Alice DI;
    • Chiara Tisi, Maria;
    • Cutini, Ilaria;
    • Giovanni Carrabba, Matteo;
    • Musso, Maurizio;
    • Martino, Massimo;
    • Maria Barbui, Anna;
    • Botto, Barbara;
    • Farina, Mirko;
    • Grillo, Giovanni;
    • Patriarca, Francesca;
    • Ladetto, Marco;
    • Arcaini, Luca
    Publication type:
    Abstract
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36

    IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 42, doi. 10.1002/hon.12_2629
    By:
    • Wang, M.;
    • Jain, P.;
    • Zhang, S.;
    • Nomie, K.;
    • Wang, L.;
    • Oriabure, O.;
    • Nogueras Gonzales, G.;
    • Zhang, L.;
    • Wagner‐Bartak, N.;
    • Hagemeister, F.;
    • Samaniego, F.;
    • Westin, J.;
    • Lee, H.J.;
    • Nastoupil, L.;
    • Ok, C.;
    • Kanagal‐Shamanna, R.;
    • Chen, W.;
    • Thirumurthi, S.;
    • Santos, D.;
    • Badillo, M.
    Publication type:
    Article
    37

    COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 42, doi. 10.1002/hon.11_2629
    By:
    • Jain, P.;
    • Romaguera, J.;
    • Nomie, K.;
    • Zhang, S.;
    • Wang, L.;
    • Oriabure, O.;
    • Wagner‐Bartak, N.;
    • Zhang, L.;
    • Hagemeister, F.;
    • Samaniego, F.;
    • Westin, J.;
    • Ju Lee, H.;
    • Nastoupil, L.;
    • Iyer, S.;
    • Parmar, S.;
    • Ok, C.;
    • Kanagal‐Shamanna, R.;
    • Chen, W.;
    • Thirumurthi, S.;
    • Santos, D.
    Publication type:
    Article
    38
    39

    IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 42, doi. 10.1002/hon.12_2629
    By:
    • Wang, M.;
    • Jain, P.;
    • Zhang, S.;
    • Nomie, K.;
    • Wang, L.;
    • Oriabure, O.;
    • Nogueras Gonzales, G.;
    • Zhang, L.;
    • Wagner‐Bartak, N.;
    • Hagemeister, F.;
    • Samaniego, F.;
    • Westin, J.;
    • Lee, H.J.;
    • Nastoupil, L.;
    • Ok, C.;
    • Kanagal‐Shamanna, R.;
    • Chen, W.;
    • Thirumurthi, S.;
    • Santos, D.;
    • Badillo, M.
    Publication type:
    Article
    40

    COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 42, doi. 10.1002/hon.11_2629
    By:
    • Jain, P.;
    • Romaguera, J.;
    • Nomie, K.;
    • Zhang, S.;
    • Wang, L.;
    • Oriabure, O.;
    • Wagner‐Bartak, N.;
    • Zhang, L.;
    • Hagemeister, F.;
    • Samaniego, F.;
    • Westin, J.;
    • Ju Lee, H.;
    • Nastoupil, L.;
    • Iyer, S.;
    • Parmar, S.;
    • Ok, C.;
    • Kanagal‐Shamanna, R.;
    • Chen, W.;
    • Thirumurthi, S.;
    • Santos, D.
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47

    Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S317, doi. 10.1016/j.clml.2019.07.293
    By:
    • Phillips, Tycel;
    • Smith, Stephen D.;
    • Jurczak, Wojciech;
    • Robak, Tadeusz;
    • Stevens, Don A.;
    • Farber, Charles M.;
    • Pagel, John M.;
    • Maddocks, Kami;
    • Flinn, Ian;
    • Jedrzejczak, Wieslaw W.;
    • Goy, Andre;
    • Zinzani, Pier Luigi;
    • Zaucha, Jan;
    • Coleman, Morton;
    • Chen, Tianling;
    • Lee, Sun Ku;
    • Liang, Wei;
    • Seto, Anna;
    • Wang, Michael
    Publication type:
    Article
    48
    49

    Primary results from the double-blind, placebo-controlled, phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

    Published in:
    Acta Haematologica Polonica, 2022, v. 53, n. A, p. 42
    By:
    • Jurczak, Wojciech;
    • Gouill, Steven Le;
    • Jerkeman, Mats;
    • Trotman, Judith;
    • Zinzani, Pier Luigi;
    • Belada, David;
    • Boccomini, Carola;
    • Flinn, Ian W.;
    • Giri, Pratyush;
    • Goy, Andre;
    • Hamlin, Paul A.;
    • Hermine, Olivier;
    • Hernández-Rivas, José-ángel;
    • Xiaonan Hong;
    • Seok Jin Kim;
    • Lewis, David;
    • Yuko Mishima;
    • Özcan, Muhit;
    • Perini, Guilherme Fleury;
    • Pocock, Christopher
    Publication type:
    Article
    50